Setra25 mg

Setra 25 mg is indicated in Depressive illness, Obsessive-compulsive disorder, Post-traumatic stress disorder, Panic disorder

SSRIs & related anti-depressant drugs

Setra 25 mg has potent and selective inhibitory action on CNS neuronal reuptake of 5-HT resulting in increased 5-HT concentrations at the synaptic clefts, leading to facilitation of its sustained activity at the postsynaptic receptor sites. It ultimately results in an improvement of depression. Reduction of Serotonin turnover in brain by Setra 25 mg is also another contributing fact implicated in its action. Its prolonged elimination half-life offers a benefit of once daily administration.

Depressive illness: Adult: Initially 50 mg daily, increased if necessary by increments of 50 mg over several weeks to maximum 200 mg daily. Usual maintenance dose is 50 mg daily. Child and adolescent less than 18 years: Not recommended. Obsessive-compulsive disorder: Adult and adolescent over 13 years: Initially 50 mg daily, increased if necessary in steps of 50 mg over several weeks. Usual dose range is 50-200 mg daily. Child (6-12 years): Initially 25 mg daily, increased to 50 mg daily after 1 week, further increased if necessary in steps of 50 mg at intervals of at least 1 week (maximum 200 mg daily).  Post-traumatic stress disorder: Adult: Initially 25 mg daily, increased after 1 week to 50 mg daily; if response is partial and if drug is tolerated, dose can be increased in steps of 50 mg over several weeks to maximum 200 mg daily. Child and adolescent less than 18 years: Not recommended. 

Potential effects of co-administration of drugs that are highly bound to plasma proteins- As Setra 25 mg is tightly bound to plasma protein, the administration of Setra 25 mg to a patient taking another drug which is tightly bound to protein, (e.g. warfarin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect. Conversely adverse effects may result from displacement of protein bound Setra 25 mg by other tightly bound drugs. Setra 25 mg may interact with other drugs such as Cimetidine, CNS active drugs like Diazepam, Hypoglycemic drugs, Atenolol etc.

Setra 25 mg is contraindicated in patients with a known hypersensitivity to Setra 25 mg or any of the excipients of drug.

Setra 25 mg may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc.

Pregnancy: Although animal studies did not provide any evidence of teratogenicity, the safety of Setra 25 mg during human pregnancy has not been established. Lactation: Setra 25 mg is known to be excreted in breast milk. Its effects on the nursing infant have not yet been established. If treatment with Setra 25 mg is considered necessary, discontinuation of breast-feeding should be considered.

Precaution should be taken in case of liver problems, kidney diseases, seizures, heart problems and any allergies. This drug may cause dizziness or drowsiness. Caution should be taken in activities requiring alertness such as driving or using machinery. Caution is advised while using this product in the elderly because they may be more sensitive to the effects of the drug. Do not take this drug if you have taken monoamine oxidase inhibitor in the last five weeks.

Store at 25° C.